Travere Therapeutics Analyst Ratings
Travere Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/20/2023 | 19.66% | Citigroup | → $7 | Initiates Coverage On | → Neutral |
10/25/2023 | 70.94% | Piper Sandler | $19 → $10 | Maintains | Neutral |
09/29/2023 | 105.13% | Wedbush | → $12 | Reiterates | Outperform → Outperform |
09/22/2023 | 105.13% | Barclays | $31 → $12 | Maintains | Overweight |
09/22/2023 | 361.54% | B of A Securities | $41 → $27 | Maintains | Buy |
09/22/2023 | 207.69% | Guggenheim | $25 → $18 | Maintains | Buy |
09/22/2023 | 139.32% | Evercore ISI Group | $30 → $14 | Maintains | Outperform |
09/22/2023 | 207.69% | HC Wainwright & Co. | $32 → $18 | Maintains | Buy |
09/22/2023 | 36.75% | Wells Fargo | $24 → $8 | Downgrades | Overweight → Equal-Weight |
09/21/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
09/19/2023 | 412.82% | Evercore ISI Group | $30 → $30 | Maintains | Outperform |
09/06/2023 | 412.82% | Evercore ISI Group | → $30 | Reinstates | Outperform → Outperform |
08/18/2023 | 224.79% | Piper Sandler | $22 → $19 | Maintains | Neutral |
08/07/2023 | 447.01% | HC Wainwright & Co. | $35 → $32 | Reiterates | Buy → Buy |
07/21/2023 | 344.44% | JP Morgan | → $26 | Initiates Coverage On | → Overweight |
07/18/2023 | 498.29% | Canaccord Genuity | $37 → $35 | Maintains | Buy |
06/21/2023 | 293.16% | Wedbush | → $23 | Reiterates | Outperform → Outperform |
06/07/2023 | 276.07% | Piper Sandler | → $22 | Assumes | → Neutral |
06/01/2023 | 498.29% | HC Wainwright & Co. | $22 → $35 | Reiterates | → Buy |
05/22/2023 | 412.82% | TD Cowen | → $30 | Initiates Coverage On | → Outperform |
05/02/2023 | 276.07% | HC Wainwright & Co. | $40 → $22 | Maintains | Buy |
05/02/2023 | 566.67% | B of A Securities | $52 → $39 | Maintains | Buy |
05/02/2023 | 344.44% | Evercore ISI Group | $36 → $26 | Maintains | Outperform |
05/02/2023 | 310.26% | Wells Fargo | $28 → $24 | Maintains | Overweight |
05/02/2023 | 293.16% | Guggenheim | $40 → $23 | Maintains | Buy |
04/17/2023 | 395.73% | Wedbush | $30 → $29 | Maintains | Outperform |
03/01/2023 | 532.48% | Guggenheim | → $37 | Initiates Coverage On | → Buy |
02/28/2023 | 617.95% | Canaccord Genuity | $44 → $42 | Maintains | Buy |
02/24/2023 | 583.76% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
02/22/2023 | 652.14% | Canaccord Genuity | $40 → $44 | Maintains | Buy |
02/21/2023 | 686.32% | Piper Sandler | $42 → $46 | Maintains | Overweight |
02/21/2023 | 412.82% | Wedbush | → $30 | Upgrades | Neutral → Outperform |
02/21/2023 | 429.91% | Barclays | $37 → $31 | Maintains | Overweight |
02/21/2023 | 583.76% | HC Wainwright & Co. | $36 → $40 | Reiterates | → Buy |
02/17/2023 | 515.38% | HC Wainwright & Co. | → $36 | Reiterates | → Buy |
01/30/2023 | 583.76% | Canaccord Genuity | $33 → $40 | Maintains | Buy |
01/11/2023 | 617.95% | Piper Sandler | $38 → $42 | Maintains | Overweight |
12/14/2022 | 276.07% | Stifel | → $22 | Initiates Coverage On | → Hold |
12/05/2022 | 378.63% | Wells Fargo | → $28 | Initiates Coverage On | → Overweight |
10/20/2022 | 549.57% | SVB Leerink | $45 → $38 | Maintains | Outperform |
10/17/2022 | 515.38% | HC Wainwright & Co. | $42 → $36 | Maintains | Buy |
10/14/2022 | 549.57% | Piper Sandler | $39 → $38 | Maintains | Overweight |
08/08/2022 | 617.95% | HC Wainwright & Co. | $46 → $42 | Maintains | Buy |
08/05/2022 | 669.23% | SVB Leerink | $42 → $45 | Maintains | Outperform |
07/26/2022 | 600.85% | Piper Sandler | $40 → $41 | Maintains | Overweight |
07/14/2022 | 617.95% | Canaccord Genuity | → $42 | Assumes | → Buy |
05/17/2022 | 686.32% | HC Wainwright & Co. | $45 → $46 | Maintains | Buy |
05/06/2022 | 583.76% | Piper Sandler | $42 → $40 | Maintains | Overweight |
03/31/2022 | 617.95% | Piper Sandler | → $42 | Initiates Coverage On | → Overweight |
02/28/2022 | 669.23% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
12/16/2021 | 583.76% | Barclays | $36 → $40 | Maintains | Overweight |
12/16/2021 | 617.95% | SVB Leerink | $37 → $42 | Maintains | Outperform |
08/17/2021 | 532.48% | SVB Leerink | $27 → $37 | Maintains | Outperform |
05/27/2021 | 669.23% | Canaccord Genuity | $48 → $45 | Maintains | Buy |
05/26/2021 | 224.79% | Wedbush | → $19 | Downgrades | Outperform → Neutral |
05/17/2021 | 720.51% | Canaccord Genuity | $51 → $48 | Maintains | Buy |
02/03/2021 | 771.79% | Canaccord Genuity | $28 → $51 | Maintains | Buy |
日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
11/20/2023 | 19.66% | 花旗集團 | → 7 美元 | 啓動覆蓋範圍開啓 | → 中立 |
2023 年 10 月 25 日 | 70.94% | 派珀·桑德勒 | 19 美元 → 10 美元 | 維護 | 中立 |
09/29/2023 | 105.13% | Wedbush | → 12 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
09/22/2023 | 105.13% | 巴克萊 | 31 美元 → 12 美元 | 維護 | 超重 |
09/22/2023 | 361.54% | B of A 類證券 | 41 美元 → 27 美元 | 維護 | 購買 |
09/22/2023 | 207.69% | 古根海姆 | 25 美元 → 18 美元 | 維護 | 購買 |
09/22/2023 | 139.32% | Evercore ISI 集團 | 30 美元 → 14 美元 | 維護 | 跑贏大盤 |
09/22/2023 | 207.69% | HC Wainwright & Co. | 32 美元 → 18 美元 | 維護 | 購買 |
09/22/2023 | 36.75% | 富國銀行 | 24 美元 → 8 美元 | 降級 | 超重 → 重量相等 |
09/21/2023 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
09/19/2023 | 412.82% | Evercore ISI 集團 | 30 美元 → 30 美元 | 維護 | 跑贏大盤 |
09/06/2023 | 412.82% | Evercore ISI 集團 | → 30 美元 | 恢復 | 跑贏大盤 → 跑贏大盤 |
08/18/2023 | 224.79% | 派珀·桑德勒 | 22 美元 → 19 美元 | 維護 | 中立 |
08/07/2023 | 447.01% | HC Wainwright & Co. | 35 美元 → 32 美元 | 重申 | 購買 → 購買 |
07/21/2023 | 344.44% | 摩根大通 | → 26 美元 | 啓動覆蓋範圍開啓 | → 超重 |
07/18/2023 | 498.29% | Canaccord Genu | 37 美元 → 35 美元 | 維護 | 購買 |
06/21/2023 | 293.16% | Wedbush | → 23 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
06/07/2023 | 276.07% | 派珀·桑德勒 | → 22 美元 | 假設 | → 中立 |
06/01/2023 | 498.29% | HC Wainwright & Co. | 22 美元 → 35 美元 | 重申 | → 購買 |
05/22/2023 | 412.82% | TD Cowen | → 30 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
05/02/2023 | 276.07% | HC Wainwright & Co. | 40 美元 → 22 美元 | 維護 | 購買 |
05/02/2023 | 566.67% | B of A 類證券 | 52 美元 → 39 美元 | 維護 | 購買 |
05/02/2023 | 344.44% | Evercore ISI 集團 | 36 美元 → 26 美元 | 維護 | 跑贏大盤 |
05/02/2023 | 310.26% | 富國銀行 | 28 美元 → 24 美元 | 維護 | 超重 |
05/02/2023 | 293.16% | 古根海姆 | 40 美元 → 23 美元 | 維護 | 購買 |
04/17/2023 | 395.73% | Wedbush | 30 美元 → 29 美元 | 維護 | 跑贏大盤 |
03/01/2023 | 532.48% | 古根海姆 | → 37 美元 | 啓動覆蓋範圍開啓 | → 購買 |
02/28/2023 | 617.95% | Canaccord Genu | 44 美元 → 42 美元 | 維護 | 購買 |
02/24/2023 | 583.76% | HC Wainwright & Co. | → 40 美元 | 重申 | → 購買 |
02/22/2023 | 652.14% | Canaccord Genu | 40 美元 → 44 美元 | 維護 | 購買 |
02/21/2023 | 686.32% | 派珀·桑德勒 | 42 美元 → 46 美元 | 維護 | 超重 |
02/21/2023 | 412.82% | Wedbush | → 30 美元 | 升級 | 中性 → 跑贏大盤 |
02/21/2023 | 429.91% | 巴克萊 | 37 美元 → 31 美元 | 維護 | 超重 |
02/21/2023 | 583.76% | HC Wainwright & Co. | 36 美元 → 40 美元 | 重申 | → 購買 |
02/17/2023 | 515.38% | HC Wainwright & Co. | → 36 美元 | 重申 | → 購買 |
01/30/2023 | 583.76% | Canaccord Genu | 33 美元 → 40 美元 | 維護 | 購買 |
01/11/2023 | 617.95% | 派珀·桑德勒 | 38 美元 → 42 美元 | 維護 | 超重 |
2022 年 12 月 14 日 | 276.07% | Stifel | → 22 美元 | 啓動覆蓋範圍開啓 | → 按住 |
12/05/2022 | 378.63% | 富國銀行 | → 28 美元 | 啓動覆蓋範圍開啓 | → 超重 |
2022 年 10 月 20 日 | 549.57% | SVB Leerink | 45 美元 → 38 美元 | 維護 | 跑贏大盤 |
2022 年 10 月 17 日 | 515.38% | HC Wainwright & Co. | 42 美元 → 36 美元 | 維護 | 購買 |
2022 年 10 月 14 日 | 549.57% | 派珀·桑德勒 | 39 美元 → 38 美元 | 維護 | 超重 |
08/08/2022 | 617.95% | HC Wainwright & Co. | 46 美元 → 42 美元 | 維護 | 購買 |
08/05/2022 | 669.23% | SVB Leerink | 42 美元 → 45 美元 | 維護 | 跑贏大盤 |
07/26/2022 | 600.85% | 派珀·桑德勒 | 40 美元 → 41 美元 | 維護 | 超重 |
07/14/2022 | 617.95% | Canaccord Genu | → 42 美元 | 假設 | → 購買 |
05/17/2022 | 686.32% | HC Wainwright & Co. | 45 美元 → 46 美元 | 維護 | 購買 |
2022 年 6 月 5 日 | 583.76% | 派珀·桑德勒 | 42 美元 → 40 美元 | 維護 | 超重 |
03/31/2022 | 617.95% | 派珀·桑德勒 | → 42 美元 | 啓動覆蓋範圍開啓 | → 超重 |
02/28/2022 | 669.23% | HC Wainwright & Co. | → 45 美元 | 啓動覆蓋範圍開啓 | → 購買 |
2021 年 12 月 16 日 | 583.76% | 巴克萊 | 36 美元 → 40 美元 | 維護 | 超重 |
2021 年 12 月 16 日 | 617.95% | SVB Leerink | 37 美元 → 42 美元 | 維護 | 跑贏大盤 |
2021 年 8 月 17 日 | 532.48% | SVB Leerink | 27 美元 → 37 美元 | 維護 | 跑贏大盤 |
05/27/2021 | 669.23% | Canaccord Genu | 48 美元 → 45 美元 | 維護 | 購買 |
2021 年 5 月 26 日 | 224.79% | Wedbush | → 19 美元 | 降級 | 跑贏大盤 → 中立 |
05/17/2021 | 720.51% | Canaccord Genu | 51 美元 → 48 美元 | 維護 | 購買 |
02/03/2021 | 771.79% | Canaccord Genu | 28 美元 → 51 美元 | 維護 | 購買 |
What is the target price for Travere Therapeutics (TVTX)?
Travere Therapeutics(TVTX)的目標價格是多少?
The latest price target for Travere Therapeutics (NASDAQ: TVTX) was reported by Citigroup on November 20, 2023. The analyst firm set a price target for $7.00 expecting TVTX to rise to within 12 months (a possible 19.66% upside). 39 analyst firms have reported ratings in the last year.
花旗集團於2023年11月20日公佈了Travere Therapeutics(納斯達克股票代碼:TVTX)的最新目標股價。該分析公司將目標股價設定爲7.00美元,預計TVTX將在12個月內上漲(可能上漲19.66%)。去年有39家分析公司公佈了評級。
What is the most recent analyst rating for Travere Therapeutics (TVTX)?
Travere Therapeutics(TVTX)的最新分析師評級是多少?
The latest analyst rating for Travere Therapeutics (NASDAQ: TVTX) was provided by Citigroup, and Travere Therapeutics initiated their neutral rating.
Travere Therapeutics(納斯達克股票代碼:TVTX)的最新分析師評級由花旗集團提供,Travere Therapeutics啓動了中性評級。
When is the next analyst rating going to be posted or updated for Travere Therapeutics (TVTX)?
Travere Therapeutics(TVTX)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Travere Therapeutics的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應獲得4個評級。Travere Therapeutics的最後一次評級是在2023年11月20日發佈的,因此您應該預計下一個評級將在2024年11月20日左右公佈。
Is the Analyst Rating Travere Therapeutics (TVTX) correct?
分析師對Travere Therapeutics(TVTX)的評級是否正確?
While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a initiated with a price target of $0.00 to $7.00. The current price Travere Therapeutics (TVTX) is trading at is $5.85, which is within the analyst's predicted range.
儘管評級是主觀的,而且將發生變化,但Travere Therapeutics(TVTX)的最新評級是啓動的,目標股價爲0.00美元至7.00美元。Travere Therapeutics(TVTX)目前的交易價格爲5.85美元,在分析師的預測區間內。